The problem for BLT is the time line and cost profile to move...

The problem for BLT is the time line and cost profile to move this from mice to humans is HUGE, both in terms of number of years to get through the multiple FDA (or whatever country you choose) obstacles and the cost to do so.

Reality its an interesting and potentially great product but timeline and cost to fund the timeline mean it is best within a multinational's portfolio not a tiny AU companies, especially one with less than 1 year of funding.